Other traditional means of reversing anticoagulants, such as fresh frozen plasma or activated factor VIIa had limited efficacy. To neutralize dabigatran, activated charcoal could be used if recently ingested, or dialysis to physically remove drug. In the early years, there were no specific reversal agents or antidotes for these drugs. The next several years, factor Xa DOAC, including rivaroxaban and apixaban were approved for use. The first DOAC, dabigatran or Pradaxa, was approved for use in the US in 2010.
This session is a joint effort between the American Association for Clinical Chemistry (AACC) and the North American Specialized Coagulation Laboratory Association (NASCOLA) Slide 3: Welcome to this Pearl of Laboratory Medicine on “ Reversal strategies for DOACs: Laboratory role?.” This program was created with Dr Dot Adcock, the Chief Medical Officer and SVP of LabCorp. I currently serve as a volunteer with UC Davis Thrombosis & Hemostasis Center after my retirement in 2017 from the university health system as the senior Clinical Laboratory Scientist in special coagulation.
0 kommentar(er)
